Abstract
The diversity and rarity of sarcomas has led to many challenges in the management of these malignancies. While local control can often be provided by surgical resection and radiation therapy, there is still a need for more effective systemic treatments in order to prevent distant recurrence and manage metastatic disease. Recent work has elucidated the underlying molecular biology in a handful of sarcoma subtypes, thereby providing avenues for targeted systemic therapy. Unfortunately, for the majority of sarcoma histological subtypes, systemic therapy continues to rely on traditional chemotherapy, often with toxic side effects. Patient-derived mouse models of sarcoma are paving the way for more personalized and targeted therapy that is both patient and tumor specific. Early trials in both subcutaneous and orthotopic models have begun to demonstrate the potential for translating xenograft findings to clinical care and represent an opportunity to personalize treatment for sarcoma patients and ultimately improve the outcomes of patients with these aggressive malignancies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hiroshima Y, Zhang Y, Zhang N, et al. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. Anticancer Res. 2015;35:697–701.
Sampson VB, Kamara DF, Kolb EA. Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing’s sarcoma: tumor models for cancer drug discovery. Expert Opin Drug Discov. 2013;8:1181–9. doi:10.1517/17460441.2013.817988.
Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer. 2004;101(10):2270–5.
Eilber FC, Kattan MW. Sarcoma nomogram: validation and a model to evaluate impact of therapy. J Am Coll Surg. 2007;205(Suppl 4):S90–5.
Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276–85.
Antman KH. Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol. 1992;19(6 Suppl 12):13–20.
Antman KH, Ryan L, Elias A, Sherman D, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7(1):126–31.
Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23. doi:10.1016/S1470-2045(14)70063-4.
Eilber FC, Rosen G, Eckardt J, Forscher C, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–9.
Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.
Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667–72.
Mullen JT, Kobayashi W, Wang JJ, Harmon DC. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012;118(15):3758–65.
Donahue TR, Kattan MW, Nelson SD, et al. Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram. Cancer. 2010;116:3883–91. doi:10.1002/cncr.25271.
Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumor to ‘nude’ mice. Acta Pathol Microbiol Scand. 1969;77:758–60.
Kirsch DG, Dinulescu DM, Miller JB, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007;13:992–7. doi:10.1038/nm1602.
Dodd RD, Añó L, Blum JM, et al. Methods to generate genetically engineered mouse models of soft tissue sarcoma. Methods Mol Biol. 2015;1267:283–95.
Puzio-Kuter AM, Laddha SV, Castillo-Martin M, et al. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma. Cell Death Differ. 2015;22:1785–91. doi:10.1038/cdd.2015.27.
Gregorian C, Nakashima J, Dry SM, et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A. 2009;106:19479–84. doi:10.1073/pnas.0910398106.
Minas TZ, Surdez D, Javaheri T, et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. 2016. doi:10.18632/oncotarget.9388
Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res. 1982;42:535–9.
Izumchenko E, Meir J, Bedi A, et al. Patient-derived xenografts as tools in pharmaceutical development. Clin Pharmacol Ther. 2016;99:612–21. doi:10.1002/cpt.354.
Monsma DJ, Cherba DM, Richardson PJ, et al. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer. 2014;61:1570–7. doi:10.1002/pbc.25039.
Hooper JE, Cantor EL, Ehlen MS, et al. Research article: a patient-derived xenograft model of parameningeal embryonal rhabdomyosarcoma for preclinical studies. Sarcoma. 2015:1–7. doi:10.1155/2015/826124.
Castellsagué J, Gel B, RodrÃguez JF, et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med. 2015;7:608–27. doi:10.15252/emmm.201404430.
Glaser G, Weroha SJ, Becker MA, et al. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One. 2015;10:e0126867–15. doi:10.1371/journal.pone.0126867.
Press JZ, Kenyon JA, Xue H, et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 2008;110:256–64.
Stebbing J, Paz K, Schwartz GK, et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer. 2014;120:2006–15. doi:10.1002/cncr.28696.
Hiroshima Y, Maawy A, Zhang Y, Zhang N, Murakami T, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Hoffman RM. Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. Oncotarget. 2016;7(44):71696–702.
Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res. 1990;50:6130–8.
Hoffman RM. Orthotopic is orthodox: why are orthotopic‑transplant metastatic models different from all other models? J Cell Biochem. 1994;56:1‑3.
Garber K. Realistic rodents? Debate grows over new mouse models of cancer. J Natl Cancer Inst. 2006;98:1176–8.
Fu X, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A. 1991;88:9345–9.
Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically from histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992;89:5645–9.
Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999;17:343–59.
Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015;15:451–2.
Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis. 1993;11:5–14. doi:10.1007/BF00880061.
Hiroshima Y, Zhang Y, Zhang N, et al. Establishment of a patient-derived orthotopic xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One. 2015;10:e0117417.
Wang X, Fu X, Hoffman RM. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer. 1992;51:992–5. doi:10.1002/ijc.2910510626.
Furukawa T, Fu X, Kubota T, et al. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res. 1993;53:1204–8.
Furukawa T, Kubota T, Watanabe M, et al. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer. 1993;53:608–12. doi:10.1002/ijc.2910530414.
Fu X, Le P, Hoffman RM. A metastatic-orthotopic transplant nude-mouse model of human patient breast cancer. Anticancer Res. 1993;13:901–4.
DeRose YS, Wang G, Lin Y-C, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514–20.
Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993;13:287–91.
Astoul P, Wang X, Colt HG, Boutin C, Hoffman RM. A patient-like human malignant pleural mesothelioma nude-mouse model. Oncol Rep. 1996;3:483–7.
Hiroshima Y, Maawy A, Metildi CA. Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. J Laparoendosc Adv Surg Tech A. 2014;24:241–7.
Shoji T, Konno H, Tanaka T, et al. Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2. Cancer Lett. 2003;195(2):235–41.
Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013. doi:10.1158/2159-8290.CD-14-0001.
Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem. 1994;56(1):4–8.
Smith KB, Tran LM, Tam BM, et al. Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. Am J Pathol. 2013;182:1400–11. doi:10.1016/j.ajpath.2013.01.002.
Murakami T, Singh AS, Kiyuna T, et al. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing’s sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2016;7:47556–64. doi:10.18632/oncotarget.9879.
Eckardt M, Russell TA, Murakami T, et al Factors impacting the establishment of individual soft tissue sarcoma patient-derived orthotopic xenograft (PDOX) mouse models: a UCLA Sarcoma Program Prospective Clinical Trial. Connective Tissue Oncology Society Annual Meeting, Lisbon, Portugal. 2016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Russell, T.A., Elliott, I.A., Singh, A.S., Eilber, F.C. (2017). Patient-Derived Mouse Models of Sarcoma. In: Hoffman, R. (eds) Patient-Derived Mouse Models of Cancer . Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-57424-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-57424-0_9
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-57423-3
Online ISBN: 978-3-319-57424-0
eBook Packages: MedicineMedicine (R0)